Silence Therapeutics (Silence Therapeutics) Price-to-Operating-Cash-Flow : (As of Apr. 29, 2024)

View and export this data going back to 2020. Start your Free Trial

What is Silence Therapeutics Price-to-Operating-Cash-Flow?

As of today (2024-04-29), Silence Therapeutics's share price is $22.10. Silence Therapeutics's Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Dec. 2023 was $-1.33. Hence, Silence Therapeutics's Price-to-Operating-Cash-Flow Ratio for today is .

The historical rank and industry rank for Silence Therapeutics's Price-to-Operating-Cash-Flow or its related term are showing as below:

During the past 13 years, Silence Therapeutics's highest Price-to-Operating-Cash-Flow Ratio was 76.70. The lowest was 28.41. And the median was 52.32.

SLN's Price-to-Operating-Cash-Flow is not ranked ^*
in the Biotechnology industry.
Industry Median: 24.7
* Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.

Silence Therapeutics's Cash Flow from Operations per share for the three months ended in Dec. 2023 was $-0.39. Its Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Dec. 2023 was $-1.33.

During the past 3 years, the average Operating Cash Flow per Share Growth Rate was -36.30% per year.

During the past 13 years, Silence Therapeutics's highest 3-Year average Operating Cash Flow per Share Growth Rate was 56.00% per year. The lowest was -36.30% per year. And the median was 6.50% per year.

Silence Therapeutics Price-to-Operating-Cash-Flow Historical Data

The historical data trend for Silence Therapeutics's Price-to-Operating-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Silence Therapeutics Price-to-Operating-Cash-Flow Chart

Silence Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Price-to-Operating-Cash-Flow

Get a 7-Day Free Trial

156.67

70.10

Silence Therapeutics Quarterly Data
	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Price-to-Operating-Cash-Flow	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of Silence Therapeutics's Price-to-Operating-Cash-Flow

For the Biotechnology subindustry, Silence Therapeutics's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Silence Therapeutics's Price-to-Operating-Cash-Flow Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Silence Therapeutics's Price-to-Operating-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Silence Therapeutics's Price-to-Operating-Cash-Flow falls into.

Silence Therapeutics Price-to-Operating-Cash-Flow Calculation

Silence Therapeutics's Price-to-Operating-Cash-Flow ratio for today is calculated as

Price-to-Operating-Cash-Flow Ratio	=	Share Price	/	Cash Flow from Operations per share (TTM)
	=	22.10	/	-1.328
	=

Silence Therapeutics's Share Price of today is $22.10.
Silence Therapeutics's Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.33.

Note: Cash Flow from Operations per share is calculated as Cash Flow from Operations divided by Shares Outstanding (Diluted Average).

It can also be calculated from the numbers for the whole company:

Price-to-Operating-Cash-Flow Ratio

Market Cap

Cash Flow from Operations

Silence Therapeutics Price-to-Operating-Cash-Flow Related Terms

Thank you for viewing the detailed overview of Silence Therapeutics's Price-to-Operating-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.

Silence Therapeutics (Silence Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Silence Therapeutics PLC (NAS:SLN) » Definitions » Price-to-Operating-Cash-Flow

Comparable Companies

Traded in Other Exchanges

SLNCF:USA XRP2:Germany

Address

72 Hammersmith Road, London, GBR, W14 8TH

Website

https://www.silence-therapeutics.com

Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid. its pipeline products are; SLN360 therapy designed to temporarily block a specific gene's message that would otherwise trigger an unwanted effect. By silencing the LPA gene, the levels of Lp(a) are lowered, which in turn is expected to lower the risk of heart diseases, heart attacks, and strokes, and SLN124 therapy aims to temporarily silence TMPRSS6, a gene that prevents the liver from producing a particular hormone that controls iron levels in the body hepcidin. As hepcidin increases, iron levels in the blood are expected to decrease, which may increase the production of healthy red blood cells, thereby reducing anemia.